Cat. No.: HY-N7694

Isotoosendanin

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Isotoosendanin is an orally active TGFβR1 inhibitor and abrogating its kinase activity (IC₅₀ = 6732 nM). Isotoosendanin inhibits the JAK/STAT3 signaling pathway by directly targeting SHP-2, enhancing its stability, and reducing its ubiquitination. Isotoosendanin inhibits TGF-β-induced reduces the migration, invasion, and metastasis in triple-negative breast cancer (TNBC) cells. Isotoosendanin exhibits anti-tumor efficacy in TNBC xenograft models and A549 xenograft tumors. Isotoosendanin exhibits significant anti-inflammatory effects in acetic acid-induced vascular permeability and λ-carrageenan-induced hind paw edema tests. Isotoosendanin can be used for the study of non-small cell lung cancer (NSCLC), TNBC and inflammation.

For research use only. We do not sell to patients.

Purity: 99.51%
CAS No.: 97871-44-8
Formula: C₃₀H₃₈O₁₁
Molecular Weight:574.62

Storage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Isotoosendanin Chemical Structure

CAS No.: 97871-44-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All TGF-β Receptor Isoforms :

All JAK Isoforms :

All STAT Isoforms :

In Vitro

Isotoosendanin (10-1000 nM, 24 h) reduces wound closure, invasion, invadopodia formation and migration of MDA-MB-231, BT549, and 4T1 TNBC cells in a concentration-dependent manner^[1].
Isotoosendanin (300-1000 nM, 24 h) reverses TGF-β-induced EMT in MDA-MB-231, BT549, and 4T1 TNBC cells by decreasing Vimentin, α-SMA, FSP1, Snail, ZEB1 expression and increasing E-cadherin expression, while reducing Smad2/3 phosphorylation^[1].
Isotoosendanin (10-1000 nM) directly interacts with TGFbR1, abrogates its kinase activity (IC₅₀ = 6732 nM), and reduces its binding with Smad2/3 in MDA-MB-231, BT549, and 4T1 TNBC cells^[1].
Isotoosendanin (0-90 μM, 48-72 h) reduces the viability of NSCLC cells such as A549, HCC827, and H838 in a dose- and time-dependent manner, with IC₅₀ values ranging from 1.691 to 18.20 µM^[2].
Isotoosendanin (1-6 μM, 72 h) significantly inhibits colony formation and proliferation (EdU assay) of A549, HCC827, and H838 cells^[2].
Isotoosendanin (1-6 μM, 24-72 h) induces G0/G1 phase arrest in A549, HCC827, and H838 cells, reduces the expression of CDK2 and Cyclin D1/A2; promotes cell apoptosis, increases the expression of Bax and Cleaved Caspase-3, and decreases the expression of Survivin and inactive Caspase-3^[2].
Isotoosendanin (1-6 μM , 72 h) reduces the phosphorylation level of STAT3 (Tyr705) in A549, HCC827, and H838 cells in a dose-dependent manner, inhibits STAT3 nuclear translocation, and suppresses IL-6/EGF-induced STAT3 phosphorylation as well as JAK2/3 and TYK2 phosphorylation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

TGF-β-induced MDA-MB-231, BT549, and 4T1 TNBC cells
Concentration:

300, 1000 nM
Incubation Time:

24 h
Result:

Decreased Vimentin, α-SMA, FSP1, Snail, ZEB1 expression.
Increased E-cadherin expression.
Reduced Smad2/3 phosphorylation.

Cell Cycle Analysis^[2]

Cell Line:

A549, HCC827, and H838 cells
Concentration:

1, 2, 4, 6 μM
Incubation Time:

72 h
Result:

Induced G0/G1 phase arrest in A549, HCC827, and H838 cells.

Apoptosis Analysis^[2]

Cell Line:

A549, HCC827, and H838 cells
Concentration:

1, 2, 4, 6 μM
Incubation Time:

24 h
Result:

Promoted cell apoptosis.
Increased the expression of Bax and Cleaved Caspase-3.
Decreased the expression of Survivin and inactive Caspase-3.

Western Blot Analysis^[2]

Cell Line:

A549, HCC827, and H838 cells
Concentration:

1, 2, 4, 6 μM
Incubation Time:

72 h
Result:

Reduced the phosphorylation level of STAT3 (Tyr705).
Inhibited STAT3 nuclear translocation.
Suppressed IL-6/EGF-induced STAT3 phosphorylation as well as JAK2/3 and TYK2 phosphorylation.

In Vivo

Isotoosendanin (0.1-1 mg/kg, i.g., daily, 2 months) reduces TNBC metastasis in MDA-MB-231-luc-GFP and BT549-luc-GFP xenograft models^[1].
Isotoosendanin (1 mg/kg, i.g., daily, 2 months) shows no additional anti-metastatic effect in TGFbR1-knockdown MDA-MB-231 xenograft model compared to the knockdown alone, as both reduce metastasis and reverse EMT^[1]. Isotoosendanin (1 mg/kg, i.g., daily, 2 months) fails to inhibit metastasis and reverse EMT in TGFbR1-overexpressed MDA-MB-231 xenograft model^[1].
Isotoosendanin (0.1-1 mg/kg, i.g., daily, 1 month) reduces TNBC metastasis in 4T1-luc-GFP xenograft model when used alone or combined with anti-PD-L1^[1].
Isotoosendanin (10-20 mg/kg, i.p., once every two days, 7 times) significantly reduces the growth of A549 xenograft tumors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MDA-MB-231-luc-GFP, BT549-luc-GFP or 4T1 cells (1×10⁶ per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice^[1]
Dosage:

0.1, 1 mg/kg
Administration:

i.g. daily for 2 months
Result:

Reduced bioluminescence signal of metastases.
Decreased number of metastatic foci in liver and lung.
Reversed EMT in tumor tissues, with decreased Vimentin, α-SMA, FSP1 expression and increased E-cadherin expression.

Animal Model:

MDA-MB-231-luc-GFP-shTGFbR1 cells (1×10⁶ per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice^[1]
Dosage:

1 mg/kg
Administration:

i.g. daily for 1 or 2 months
Result:

Showed no additional reduction in bioluminescence signal of metastases compared to TGFbR1 knockdown alone at 1 mg/kg/day.
Showed no additional decrease in number of metastatic foci in liver and lung compared to TGFbR1 knockdown alone.
Showed no additional reversal of EMT in tumor tissues compared to TGFbR1 knockdown alone.

Animal Model:

MDA-MB-231-luc-GFP-TGFbR1 cells (1×10⁶ per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice^[1]
Dosage:

1 mg/kg
Administration:

i.g. daily for 2 months
Result:

Failed to reduce bioluminescence signal of metastases at 1 mg/kg/day (p.o., 2 months).
Failed to decrease number of metastatic foci in liver and lung.
Lost the ability to reverse EMT in tumor tissues.

Animal Model:

4T1 cells (1×10⁶ per mouse) were subcutaneously injected into the fourth right mammary fat pad at the base of the nipple of 4-week-old female BALB/c nude mice^[1]
Dosage:

0.1, 1 mg/kg
Administration:

i.g. daily for 1 months
Result:

Enhanced inhibition of tumor growth when combined with anti-PD-L1 at 1 mg/kg/day.
Prolonged survival time of mice compared to monotherapy.
Reduced collagen deposition in tumor microenvironment.
Promoted infiltration of TILs, DCs, and cytotoxic T cells (CD3⁺, Granzyme B⁺, CD107a⁺, CD8⁺ T cells) in tumor microenvironment.
Reversed EMT in tumor tissues more effectively than monotherapy.

Animal Model:

A549 cells were subcutaneously injected into BALB/c nude mice (female, 4-5 weeks old, 18-20 g) to establish a xenograft model^[2].
Dosage:

10, 20 mg/kg
Administration:

i.p. once every two days for 7 times
Result:

Reduced tumor volume and weight in A549 xenograft models.
Showed no significant change in mice body weight.
Increased expression of SHP-2, p-SHP-2 (Tyr542) and p-SHP-2 (Tyr580) in tumor tissues.
Decreased expression of p-STAT3 (Tyr705) and PCNA in tumor tissues.
Reduced expression of Cyclin D1, CDK2 and Survivin in tumor tissues.
Increased expression of Bax in tumor tissues.

Chemical Information

CAS No. 97871-44-8
Appearance Solid
Molecular Weight 574.62
Formula C₃₀H₃₈O₁₁
Color White to off-white
SMILES

O[C@@H](C[C@H]1OC(C)=O)[C@]([C@](C[C@H]2O)([H])[C@@]31C)(COC3O)[C@](C([C@@H]4OC(C)=O)=O)([H])[C@@]2([C@@](C5=O)([H])[C@@]4([C@@](C6=COC=C6)([H])C5)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Ecotoxicol Environ Saf

Multi-level bioinformatics combined with in vitro and in vivo experiments reveal the nephrotoxicity risk of isotoosendanin. [Abstract]

2025 Oct 28:306:119288. PMID: 41161241

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (43.51 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7403 mL

8.7014 mL

17.4028 mL

5 mM

0.3481 mL

1.7403 mL

3.4806 mL

10 mM

0.1740 mL

0.8701 mL

1.7403 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (294 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang J, et al. Isotoosendanin exerts inhibition on triple-negative breast cancer through abrogating TGF-β-induced epithelial-mesenchymal transition via directly targeting TGFβR1. Acta Pharm Sin B. 2023 Jul;13(7):2990-3007. [Content Brief]

[2]. Shu C, et al. Isotoosendanin exerts anti-tumor effects in NSCLC by enhancing the stability of SHP-2 and inhibiting the JAK/STAT3 pathway. Phytomedicine. 2024 Sep;132:155832. [Content Brief]

[3]. Xie F, et al. Anti-inflammatory and analgesic activities of ethanolic extract and two limonoids from Melia toosendan fruit. J Ethnopharmacol. 2008 May 22;117(3):463-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7403 mL	8.7014 mL	17.4028 mL	43.5070 mL
	5 mM	0.3481 mL	1.7403 mL	3.4806 mL	8.7014 mL
	10 mM	0.1740 mL	0.8701 mL	1.7403 mL	4.3507 mL
	15 mM	0.1160 mL	0.5801 mL	1.1602 mL	2.9005 mL
	20 mM	0.0870 mL	0.4351 mL	0.8701 mL	2.1754 mL
	25 mM	0.0696 mL	0.3481 mL	0.6961 mL	1.7403 mL
	30 mM	0.0580 mL	0.2900 mL	0.5801 mL	1.4502 mL
	40 mM	0.0435 mL	0.2175 mL	0.4351 mL	1.0877 mL

Keywords

Isotoosendanin

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Isotoosendanin

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Isotoosendanin

All TGF-β Receptor Isoforms

All JAK Isoforms

All STAT Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Isotoosendanin Related Classifications

Cat. No.: HY-N7694